Showing 1–10 of 10 results for author: Benrimoh, D

Development and Validation of a Deep-Learning Model for Differential Treatment Benefit Prediction for Adults with Major Depressive Disorder Deployed in the Artificial Intelligence in Depression Medication Enhancement (AIDME) Study

Authors: David Benrimoh, Caitrin Armstrong, Joseph Mehltretter, Robert Fratila, Kelly Perlman, Sonia Israel, Adam Kapelner, Sagar V. Parikh, Jordan F. Karp, Katherine Heller, Gustavo Turecki

Abstract: INTRODUCTION: The pharmacological treatment of Major Depressive Disorder (MDD) relies on a trial-and-error approach. We introduce an artificial intelligence (AI) model aiming to personalize treatment and improve outcomes, which was deployed in the Artificial Intelligence in Depression Medication Enhancement (AIDME) Study. OBJECTIVES: 1) Develop a model capable of predicting probabilities of remiss… ▽ More INTRODUCTION: The pharmacological treatment of Major Depressive Disorder (MDD) relies on a trial-and-error approach. We introduce an artificial intelligence (AI) model aiming to personalize treatment and improve outcomes, which was deployed in the Artificial Intelligence in Depression Medication Enhancement (AIDME) Study. OBJECTIVES: 1) Develop a model capable of predicting probabilities of remission across multiple pharmacological treatments for adults with at least moderate major depression. 2) Validate model predictions and examine them for amplification of harmful biases. METHODS: Data from previous clinical trials of antidepressant medications were standardized into a common framework and included 9,042 adults with moderate to severe major depression. Feature selection retained 25 clinical and demographic variables. Using Bayesian optimization, a deep learning model was trained on the training set, refined using the validation set, and tested once on the held-out test set. RESULTS: In the evaluation on the held-out test set, the model demonstrated achieved an AUC of 0.65. The model outperformed a null model on the test set (p = 0.01). The model demonstrated clinical utility, achieving an absolute improvement in population remission rate in hypothetical and actual improvement testing. While the model did identify one drug (escitalopram) as generally outperforming the other drugs (consistent with the input data), there was otherwise significant variation in drug rankings. On bias testing, the model did not amplify potentially harmful biases. CONCLUSIONS: We demonstrate the first model capable of predicting outcomes for 10 different treatment options for patients with MDD, intended to be used at or near the start of treatment to personalize treatment. The model was put into clinical practice during the AIDME randomized controlled trial whose results are reported separately. △ Less

Submitted 7 June, 2024; originally announced June 2024.

A computational account of the development and evolution of psychotic symptoms

Authors: Albert Powers, Philip Angelos, Alexandria Bond, Emily Farina, Carolyn Fredericks, Jay Gandhi, Maximillian Greenwald, Gabriela Hernandez-Busot, Gabriel Hosein, Megan Kelley, Catalina Mourgues, William Palmer, Julia Rodriguez-Sanchez, Rashina Seabury, Silmilly Toribio, Raina Vin, Jeremy Weleff, David Benrimoh

Abstract: The mechanisms of psychotic symptoms like hallucinations and delusions are often investigated in fully-formed illness, well after symptoms emerge. These investigations have yielded key insights, but are not well-positioned to reveal the dynamic forces underlying symptom formation itself. Understanding symptom development over time would allow us to identify steps in the pathophysiological process… ▽ More The mechanisms of psychotic symptoms like hallucinations and delusions are often investigated in fully-formed illness, well after symptoms emerge. These investigations have yielded key insights, but are not well-positioned to reveal the dynamic forces underlying symptom formation itself. Understanding symptom development over time would allow us to identify steps in the pathophysiological process leading to psychosis, shifting the focus of psychiatric intervention from symptom alleviation to prevention. We propose a model for understanding the emergence of psychotic symptoms within the context of an adaptive, develo** neural system. We will make the case for a pathophysiological process that begins with cortical hyperexcitability and bottom-up noise transmission, which engenders inappropriate belief formation via aberrant prediction error signaling. We will argue that this bottom-up noise drives learning about the (im)precision of new incoming sensory information because of diminished signal-to-noise ratio, causing an adaptive relative over-reliance on prior beliefs. This over-reliance on priors predisposes to hallucinations and covaries with hallucination severity. An over-reliance on priors may also lead to increased conviction in the beliefs generated by bottom-up noise and drive movement toward conversion to psychosis. We will identify predictions of our model at each stage, examine evidence to support or refute those predictions, and propose experiments that could falsify or help select between alternative elements of the overall model. Nesting computational abnormalities within longitudinal development allows us to account for hidden dynamics among the mechanisms driving symptom formation and to view established symptomatology as a point of equilibrium among competing biological forces. △ Less

Submitted 16 April, 2024; originally announced April 2024.

Emergence and dynamics of delusions and hallucinations across stages in early psychosis

Authors: Catalina Mourgues-Codern, David Benrimoh, Jay Gandhi, Emily A. Farina, Raina Vin, Tihare Zamorano, Deven Parekh, Ashok Malla, Ridha Joober, Martin Lepage, Srividya N. Iyer, Jean Addington, Carrie E. Bearden, Kristin S. Cadenhead, Barbara Cornblatt, Matcheri Keshavan, William S. Stone, Daniel H. Mathalon, Diana O. Perkins, Elaine F. Walker, Tyrone D. Cannon, Scott W. Woods, Jai L. Shah, Albert R. Powers

Abstract: Hallucinations and delusions are often grouped together within the positive symptoms of psychosis. However, recent evidence suggests they may be driven by distinct computational and neural mechanisms. Examining the time course of their emergence may provide insights into the relationship between these underlying mechanisms. Participants from the second (N = 719) and third (N = 699) iterations of t… ▽ More Hallucinations and delusions are often grouped together within the positive symptoms of psychosis. However, recent evidence suggests they may be driven by distinct computational and neural mechanisms. Examining the time course of their emergence may provide insights into the relationship between these underlying mechanisms. Participants from the second (N = 719) and third (N = 699) iterations of the North American Prodrome Longitudinal Study (NAPLS 2 and 3) were assessed for timing of CHR-P-level delusion and hallucination onset. Pre-onset symptom patterns in first-episode psychosis patients (FEP) from the Prevention and Early Intervention Program for Psychosis (PEPP-Montreal; N = 694) were also assessed. Symptom onset was determined at baseline assessment and the evolution of symptom patterns examined over 24 months. In all three samples, participants were more likely to report the onset of delusion-spectrum symptoms prior to hallucination-spectrum symptoms (odds ratios (OR): NAPLS 2 = 4.09; NAPLS 3 = 4.14; PEPP, Z = 7.01, P < 0.001) and to present with only delusions compared to only hallucinations (OR: NAPLS 2 = 5.6; NAPLS 3 = 11.11; PEPP = 42.75). Re-emergence of delusions after remission was also more common than re-emergence of hallucinations (Ps < 0.05), and hallucinations more often resolved first (Ps < 0.001). In both CHR-P samples, ratings of delusional ideation fell with the onset of hallucinations (P = 0.007). Delusions tend to emerge before hallucinations and may play a role in their development. Further work should examine the relationship between the mechanisms driving these symptoms and its utility for diagnosis and treatment. △ Less

Submitted 20 February, 2024; originally announced February 2024.

Evidence for Reduced Sensory Precision and Increased Reliance on Priors in Hallucination-Prone Individuals in a General Population Sample

Authors: David Benrimoh, Victoria L. Fisher, Rashina Seabury, Ely Sibarium, Catalina Mourgues, Doris Chen, Albert Powers

Abstract: There is increasing evidence that people with hallucinations overweight perceptual beliefs relative to incoming sensory evidence. Much past work demonstrating prior overweighting has used simple, non-linguistic stimuli. However, auditory hallucinations in psychosis are often complex and linguistic. There may be an interaction between the type of auditory information being processed and its perceiv… ▽ More There is increasing evidence that people with hallucinations overweight perceptual beliefs relative to incoming sensory evidence. Much past work demonstrating prior overweighting has used simple, non-linguistic stimuli. However, auditory hallucinations in psychosis are often complex and linguistic. There may be an interaction between the type of auditory information being processed and its perceived quality in engendering hallucinations. We administered a linguistic version of the Conditioned Hallucinations (CH) task to an online sample of 88 general population participants. Metrics related to hallucination-proneness, recent auditory hallucinations, stimulus thresholds, and stimulus detection were collected; data was used to fit parameters of a Hierarchical Gaussian Filter model of perceptual inference to determine how latent perceptual states influenced task behavior. Replicating past results, higher CH rates were associated with measures of higher hallucination-proneness and recent hallucinatory experiences; CH rates were positively correlated with increased prior weighting; and increased prior weighting was related to recent hallucinatory experiences. Unlike past results, participants with recent hallucinatory experiences as well as those with higher hallucination-proneness had higher stimulus thresholds, lower sensitivity to stimuli presented at the highest threshold, and tended to have lower response confidence, consistent with lower precision of sensory evidence. We show that hallucination-prone individuals in the general population have increased conditioned hallucination rates using a linguistic version of the CH task, and replicated the finding that increased CH rates and recent hallucinations correlate with increased prior weighting. Results support a role for reduced sensory precision in the interplay between prior weighting and hallucination-proneness. *contributed equally △ Less

Submitted 23 June, 2023; originally announced June 2023.

Towards Outcome-Driven Patient Subgroups: A Machine Learning Analysis Across Six Depression Treatment Studies

Authors: David Benrimoh, Akiva Kleinerman, Toshi A. Furukawa, Charles F. Reynolds III, Eric Lenze, Jordan Karp, Benoit Mulsant, Caitrin Armstrong, Joseph Mehltretter, Robert Fratila, Kelly Perlman, Sonia Israel, Myriam Tanguay-Sela, Christina Popescu, Grace Golden, Sabrina Qassim, Alexandra Anacleto, Adam Kapelner, Ariel Rosenfeld, Gustavo Turecki

Abstract: Major depressive disorder (MDD) is a heterogeneous condition; multiple underlying neurobiological substrates could be associated with treatment response variability. Understanding the sources of this variability and predicting outcomes has been elusive. Machine learning has shown promise in predicting treatment response in MDD, but one limitation has been the lack of clinical interpretability of m… ▽ More Major depressive disorder (MDD) is a heterogeneous condition; multiple underlying neurobiological substrates could be associated with treatment response variability. Understanding the sources of this variability and predicting outcomes has been elusive. Machine learning has shown promise in predicting treatment response in MDD, but one limitation has been the lack of clinical interpretability of machine learning models. We analyzed data from six clinical trials of pharmacological treatment for depression (total n = 5438) using the Differential Prototypes Neural Network (DPNN), a neural network model that derives patient prototypes which can be used to derive treatment-relevant patient clusters while learning to generate probabilities for differential treatment response. A model classifying remission and outputting individual remission probabilities for five first-line monotherapies and three combination treatments was trained using clinical and demographic data. Model validity and clinical utility were measured based on area under the curve (AUC) and expected improvement in sample remission rate with model-guided treatment, respectively. Post-hoc analyses yielded clusters (subgroups) based on patient prototypes learned during training. Prototypes were evaluated for interpretability by assessing differences in feature distributions and treatment-specific outcomes. A 3-prototype model achieved an AUC of 0.66 and an expected absolute improvement in population remission rate compared to the sample remission rate. We identified three treatment-relevant patient clusters which were clinically interpretable. It is possible to produce novel treatment-relevant patient profiles using machine learning models; doing so may improve precision medicine for depression. Note: This model is not currently the subject of any active clinical trials and is not intended for clinical use. △ Less

Submitted 30 March, 2023; v1 submitted 24 March, 2023; originally announced March 2023.

Applying Artificial Intelligence to Clinical Decision Support in Mental Health: What Have We Learned?

Authors: Grace Golden, Christina Popescu, Sonia Israel, Kelly Perlman, Caitrin Armstrong, Robert Fratila, Myriam Tanguay-Sela, David Benrimoh

Abstract: Clinical decision support systems (CDSS) augmented with artificial intelligence (AI) models are emerging as potentially valuable tools in healthcare. Despite their promise, the development and implementation of these systems typically encounter several barriers, hindering the potential for widespread adoption. Here we present a case study of a recently developed AI-CDSS, Aifred Health, aimed at su… ▽ More Clinical decision support systems (CDSS) augmented with artificial intelligence (AI) models are emerging as potentially valuable tools in healthcare. Despite their promise, the development and implementation of these systems typically encounter several barriers, hindering the potential for widespread adoption. Here we present a case study of a recently developed AI-CDSS, Aifred Health, aimed at supporting the selection and management of treatment in major depressive disorder. We consider both the principles espoused during development and testing of this AI-CDSS, as well as the practical solutions developed to facilitate implementation. We also propose recommendations to consider throughout the building, validation, training, and implementation process of an AI-CDSS. These recommendations include: identifying the key problem, selecting the type of machine learning approach based on this problem, determining the type of data required, determining the format required for a CDSS to provide clinical utility, gathering physician and patient feedback, and validating the tool across multiple settings. Finally, we explore the potential benefits of widespread adoption of these systems, while balancing these against implementation challenges such as ensuring systems do not disrupt the clinical workflow, and designing systems in a manner that engenders trust on the part of end users. △ Less

Submitted 6 March, 2023; originally announced March 2023.

Barriers and Solutions to the Adoption of Clinical Tools for Computational Psychiatry

Authors: David Benrimoh, Victoria Fisher, Catalina Mourgues, Andrew D. Sheldon, Ryan Smith, Albert R. Powers

Abstract: Computational psychiatry is a field aimed at develo** formal models of information processing in the human brain, and how alterations in this processing can lead to clinical phenomena. Despite significant progress in the development of tasks and how to model them, computational psychiatry methodologies have yet to be incorporated into large-scale research projects or into clinical practice. In t… ▽ More Computational psychiatry is a field aimed at develo** formal models of information processing in the human brain, and how alterations in this processing can lead to clinical phenomena. Despite significant progress in the development of tasks and how to model them, computational psychiatry methodologies have yet to be incorporated into large-scale research projects or into clinical practice. In this viewpoint, we explore some of the barriers to incorporation of computational psychiatry tasks and models into wider mainstream research directions. These barriers include the time required for participants to complete tasks, test-retest reliability, limited ecological validity, as well as practical concerns, such as lack of computational expertise and the expense and large sample sizes traditionally required to validate tasks and models. We then discuss solutions, such as the redesigning of tasks with a view toward feasibility, and the integration of tasks into more ecologically valid and standardized game platforms that can be more easily disseminated. Finally, we provide an example of how one task, the conditioned hallucinations task, might be translated into such a game. It is our hope that interest in the creation of more accessible and feasible computational tasks will help computational methods make more positive impacts on research as well as clinical practice. △ Less

Submitted 9 December, 2022; originally announced January 2023.

New designs for Bayesian adaptive cluster-randomized trials

Authors: Junwei Shen, Shirin Golchi, Erica E. M. Moodie, David Benrimoh

Abstract: Adaptive approaches, allowing for more flexible trial design, have been proposed for individually randomized trials to save time or reduce sample size. However, adaptive designs for cluster-randomized trials in which groups of participants rather than individuals are randomized to treatment arms are less common. Motivated by a cluster-randomized trial designed to assess the effectiveness of a mach… ▽ More Adaptive approaches, allowing for more flexible trial design, have been proposed for individually randomized trials to save time or reduce sample size. However, adaptive designs for cluster-randomized trials in which groups of participants rather than individuals are randomized to treatment arms are less common. Motivated by a cluster-randomized trial designed to assess the effectiveness of a machine-learning based clinical decision support system for physicians treating patients with depression, two Bayesian adaptive designs for cluster-randomized trials are proposed to allow for early stop** for efficacy at pre-planned interim analyses. The difference between the two designs lies in the way that participants are sequentially recruited. Given a maximum number of clusters as well as maximum cluster size allowed in the trial, one design sequentially recruits clusters with the given maximum cluster size, while the other recruits all clusters at the beginning of the trial but sequentially enrolls individual participants until the trial is stopped early for efficacy or the final analysis has been reached. The design operating characteristics are explored via simulations for a variety of scenarios and two outcome types for the two designs. The simulation results show that for different outcomes the design choice may be different. We make recommendations for designs of Bayesian adaptive cluster-randomized trial based on the simulation results. △ Less

Submitted 6 January, 2022; originally announced January 2022.

Computational Mechanism for the Effect of Psychosis Community Treatment: A Conceptual Review from Neurobiology to Social Interaction

Authors: David Benrimoh, Ely Sibarium, Andrew Sheldon, Albert Powers

Abstract: The computational underpinnings of positive psychotic symptoms have recently received significant attention. Candidate mechanisms include some combination of maladaptive priors and reduced updating of these priors during perception. A potential benefit of models with such mechanisms is their ability to link multiple levels of explanation. This is key to improving how we understand the experience o… ▽ More The computational underpinnings of positive psychotic symptoms have recently received significant attention. Candidate mechanisms include some combination of maladaptive priors and reduced updating of these priors during perception. A potential benefit of models with such mechanisms is their ability to link multiple levels of explanation. This is key to improving how we understand the experience of psychosis. Moreover, it points us towards more comprehensive avenues for therapeutic research by providing a putative mechanism that could allow for the generation of new treatments from first principles. In order to demonstrate this, our conceptual paper will discuss the application of the insights from previous computational models to an important and complex set of evidence-based clinical interventions with strong social elements, such as coordinated specialty care clinics in early psychosis and assertive community treatment. These interventions may include but also go beyond psychopharmacology, providing, we argue, structure and predictability for patients experiencing psychosis. We develop the argument that this structure and predictability directly counteract the relatively low precision afforded to sensory information in psychosis, while also providing the patient more access to external cognitive resources in the form of providers and the structure of the programs themselves. We discuss how computational models explain the resulting reduction in symptoms, as well as the predictions these models make about potential responses of patients to modifications or to different variations of these interventions. We also link, via the framework of computational models, the experiences of patients and response to interventions to putative neurobiology. △ Less

Submitted 25 March, 2021; originally announced March 2021.

Big Data Analytics and AI in Mental Healthcare

Authors: Ariel Rosenfeld, David Benrimoh, Caitrin Armstrong, Nykan Mirchi, Timothe Langlois-Therrien, Colleen Rollins, Myriam Tanguay-Sela, Joseph Mehltretter, Robert Fratila, Sonia Israel, Emily Snook, Kelly Perlman, Akiva Kleinerman, Bechara Saab, Mark Thoburn, Cheryl Gabbay, Amit Yaniv-Rosenfeld

Abstract: Mental health conditions cause a great deal of distress or impairment; depression alone will affect 11% of the world's population. The application of Artificial Intelligence (AI) and big-data technologies to mental health has great potential for personalizing treatment selection, prognosticating, monitoring for relapse, detecting and hel** to prevent mental health conditions before they reach cl… ▽ More Mental health conditions cause a great deal of distress or impairment; depression alone will affect 11% of the world's population. The application of Artificial Intelligence (AI) and big-data technologies to mental health has great potential for personalizing treatment selection, prognosticating, monitoring for relapse, detecting and hel** to prevent mental health conditions before they reach clinical-level symptomatology, and even delivering some treatments. However, unlike similar applications in other fields of medicine, there are several unique challenges in mental health applications which currently pose barriers towards the implementation of these technologies. Specifically, there are very few widely used or validated biomarkers in mental health, leading to a heavy reliance on patient and clinician derived questionnaire data as well as interpretation of new signals such as digital phenoty**. In addition, diagnosis also lacks the same objective 'gold standard' as in other conditions such as oncology, where clinicians and researchers can often rely on pathological analysis for confirmation of diagnosis. In this chapter we discuss the major opportunities, limitations and techniques used for improving mental healthcare through AI and big-data. We explore both the computational, clinical and ethical considerations and best practices as well as lay out the major researcher directions for the near future. △ Less

Submitted 12 March, 2019; originally announced March 2019.

Comments: Chapter in the "Big Data in Healthcare" book (Elsevier) [exp. 2019]